NCT04294641 2026-01-23
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
5 trialsNCT00737893 2021-04-08
ERECT
Johns Hopkins University
Phase 2 Completed
NCT01467115 2017-05-09
DREXNECK
Drexel University
Phase 2 Completed
NCT01048034 2013-10-29
Evaluation of Azacitidine in Transfusion Dependent Patients With Low-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Nordic MDS Group
Phase 2 Completed
NCT01222195 2012-08-07
Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated